883 related articles for article (PubMed ID: 26915512)
1. Polygenic overlap between schizophrenia risk and antipsychotic response: a genomic medicine approach.
Ruderfer DM; Charney AW; Readhead B; Kidd BA; Kähler AK; Kenny PJ; Keiser MJ; Moran JL; Hultman CM; Scott SA; Sullivan PF; Purcell SM; Dudley JT; Sklar P
Lancet Psychiatry; 2016 Apr; 3(4):350-7. PubMed ID: 26915512
[TBL] [Abstract][Full Text] [Related]
2. Genetic predictors of antipsychotic response to lurasidone identified in a genome wide association study and by schizophrenia risk genes.
Li J; Yoshikawa A; Brennan MD; Ramsey TL; Meltzer HY
Schizophr Res; 2018 Feb; 192():194-204. PubMed ID: 28431800
[TBL] [Abstract][Full Text] [Related]
3. Revisiting Antipsychotic Drug Actions Through Gene Networks Associated With Schizophrenia.
Kauppi K; Rosenthal SB; Lo MT; Sanyal N; Jiang M; Abagyan R; McEvoy LK; Andreassen OA; Chen CH
Am J Psychiatry; 2018 Jul; 175(7):674-682. PubMed ID: 29495895
[TBL] [Abstract][Full Text] [Related]
4. Genome-wide association study on antipsychotic-induced weight gain in Europeans and African-Americans.
Maciukiewicz M; Tiwari AK; Zai CC; Gorbovskaya I; Laughlin CP; Nurmi EL; Liebermann JA; Meltzer HY; Kennedy JL; Müller DJ
Schizophr Res; 2019 Oct; 212():204-212. PubMed ID: 31447353
[TBL] [Abstract][Full Text] [Related]
5. Preliminary evidence for association of genome-wide significant DRD2 schizophrenia risk variant with clozapine response.
Huang E; Maciukiewicz M; Zai CC; Tiwari AK; Li J; Potkin SG; Lieberman JA; Meltzer HY; Müller DJ; Kennedy JL
Pharmacogenomics; 2016; 17(2):103-9. PubMed ID: 26666695
[TBL] [Abstract][Full Text] [Related]
6. Five novel loci associated with antipsychotic treatment response in patients with schizophrenia: a genome-wide association study.
Yu H; Yan H; Wang L; Li J; Tan L; Deng W; Chen Q; Yang G; Zhang F; Lu T; Yang J; Li K; Lv L; Tan Q; Zhang H; Xiao X; Li M; Ma X; Yang F; Li L; Wang C; Li T; Zhang D; Yue W;
Lancet Psychiatry; 2018 Apr; 5(4):327-338. PubMed ID: 29503163
[TBL] [Abstract][Full Text] [Related]
7. The identification of novel genetic variants associated with antipsychotic treatment response outcomes in first-episode schizophrenia patients.
Drögemöller BI; Emsley R; Chiliza B; van der Merwe L; Wright GE; Daya M; Hoal E; Malhotra AK; Lencz T; Robinson DG; Zhang JP; Asmal L; Niehaus DJ; Warnich L
Pharmacogenet Genomics; 2016 May; 26(5):235-42. PubMed ID: 26928376
[TBL] [Abstract][Full Text] [Related]
8. Genetic overlap between antipsychotic response and susceptibility to schizophrenia.
Ikeda M; Yoshimura R; Hashimoto R; Kondo K; Saito T; Shimasaki A; Ohi K; Tochigi M; Kawamura Y; Nishida N; Miyagawa T; Sasaki T; Tokunaga K; Kasai K; Takeda M; Nakamura J; Ozaki N; Iwata N
J Clin Psychopharmacol; 2015 Feb; 35(1):85-8. PubMed ID: 25502484
[No Abstract] [Full Text] [Related]
9. Polygenic overlap with body-mass index improves prediction of treatment-resistant schizophrenia.
O'Connell KS; Koch E; Lenk HÇ; Akkouh IA; Hindley G; Jaholkowski P; Smith RL; Holen B; Shadrin AA; Frei O; Smeland OB; Steen NE; Dale AM; Molden E; Djurovic S; Andreassen OA
Psychiatry Res; 2023 Jul; 325():115217. PubMed ID: 37146461
[TBL] [Abstract][Full Text] [Related]
10. Interaction Testing and Polygenic Risk Scoring to Estimate the Association of Common Genetic Variants With Treatment Resistance in Schizophrenia.
Pardiñas AF; Smart SE; Willcocks IR; Holmans PA; Dennison CA; Lynham AJ; Legge SE; Baune BT; Bigdeli TB; Cairns MJ; Corvin A; Fanous AH; Frank J; Kelly B; McQuillin A; Melle I; Mortensen PB; Mowry BJ; Pato CN; Periyasamy S; Rietschel M; Rujescu D; Simonsen C; St Clair D; Tooney P; Wu JQ; Andreassen OA; Kowalec K; Sullivan PF; Murray RM; Owen MJ; MacCabe JH; O'Donovan MC; Walters JTR; ; Ajnakina O; Alameda L; Barnes TRE; Berardi D; Bonora E; Camporesi S; Cleusix M; Conus P; Crespo-Facorro B; D'Andrea G; Demjaha A; Do KQ; Doody GA; Eap CB; Ferchiou A; Di Forti M; Guidi L; Homman L; Jenni R; Joyce EM; Kassoumeri L; Khadimallah I; Lastrina O; Muratori R; Noyan H; O'Neill FA; Pignon B; Restellini R; Richard JR; Schürhoff F; Španiel F; Szöke A; Tarricone I; Tortelli A; Üçok A; Vázquez-Bourgon J
JAMA Psychiatry; 2022 Mar; 79(3):260-269. PubMed ID: 35019943
[TBL] [Abstract][Full Text] [Related]
11. Polygenic Risk Score for Schizophrenia and Treatment-Resistant Schizophrenia.
Wimberley T; Gasse C; Meier SM; Agerbo E; MacCabe JH; Horsdal HT
Schizophr Bull; 2017 Sep; 43(5):1064-1069. PubMed ID: 28184875
[TBL] [Abstract][Full Text] [Related]
12. Gene-set analysis based on the pharmacological profiles of drugs to identify repurposing opportunities in schizophrenia.
de Jong S; Vidler LR; Mokrab Y; Collier DA; Breen G
J Psychopharmacol; 2016 Aug; 30(8):826-30. PubMed ID: 27302942
[TBL] [Abstract][Full Text] [Related]
13. Recent Progress in Pharmacogenomics of Antipsychotic Drug Response.
Zhang JP; Malhotra AK
Curr Psychiatry Rep; 2018 Mar; 20(4):24. PubMed ID: 29589131
[TBL] [Abstract][Full Text] [Related]
14. Genome-wide association study reveals greater polygenic loading for schizophrenia in cases with a family history of illness.
Bigdeli TB; Ripke S; Bacanu SA; Lee SH; Wray NR; Gejman PV; Rietschel M; Cichon S; St Clair D; Corvin A; Kirov G; McQuillin A; Gurling H; Rujescu D; Andreassen OA; Werge T; Blackwood DH; Pato CN; Pato MT; Malhotra AK; O'Donovan MC; Kendler KS; Fanous AH;
Am J Med Genet B Neuropsychiatr Genet; 2016 Mar; 171B(2):276-89. PubMed ID: 26663532
[TBL] [Abstract][Full Text] [Related]
15. Systems-Level Analysis of Genetic Variants Reveals Functional and Spatiotemporal Context in Treatment-resistant Schizophrenia.
Talarico F; Costa GO; Ota VK; Santoro ML; Noto C; Gadelha A; Bressan R; Azevedo H; Belangero SI
Mol Neurobiol; 2022 May; 59(5):3170-3182. PubMed ID: 35278208
[TBL] [Abstract][Full Text] [Related]
16. Polygenic risk score analyses of symptoms and treatment response in an antipsychotic-naive first episode of psychosis cohort.
Santoro ML; Ota V; de Jong S; Noto C; Spindola LM; Talarico F; Gouvea E; Lee SH; Moretti P; Curtis C; Patel H; Newhouse S; Carvalho CM; Gadelha A; Cordeiro Q; Bressan RA; Belangero SI; Breen G
Transl Psychiatry; 2018 Aug; 8(1):174. PubMed ID: 30171181
[TBL] [Abstract][Full Text] [Related]
17. Pharmacogenetics of clozapine treatment response and side-effects in schizophrenia: an update.
Sriretnakumar V; Huang E; Müller DJ
Expert Opin Drug Metab Toxicol; 2015; 11(11):1709-31. PubMed ID: 26364648
[TBL] [Abstract][Full Text] [Related]
18. Genetic correlates of insight in schizophrenia.
Xavier RM; Vorderstrasse A; Keefe RSE; Dungan JR
Schizophr Res; 2018 May; 195():290-297. PubMed ID: 29054485
[TBL] [Abstract][Full Text] [Related]
19. Genetic association of the GDNF alpha-receptor genes with schizophrenia and clozapine response.
Souza RP; Romano-Silva MA; Lieberman JA; Meltzer HY; MacNeil LT; Culotti JG; Kennedy JL; Wong AH
J Psychiatr Res; 2010 Aug; 44(11):700-6. PubMed ID: 20116071
[TBL] [Abstract][Full Text] [Related]
20. Associations Between Polygenic Risk Score Loading, Psychosis Liability, and Clozapine Use Among Individuals With Schizophrenia.
Lin BD; Pinzón-Espinosa J; Blouzard E; van der Horst MZ; Okhuijsen-Pfeifer C; van Eijk KR; Guloksuz S; Peyrot WJ; Luykx JJ;
JAMA Psychiatry; 2023 Feb; 80(2):181-185. PubMed ID: 36542388
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
